Thursday, May 28, 2020 | Last Update : 02:18 PM IST

64th Day Of Lockdown

Maharashtra54758169541792 Tamil Nadu177289342128 Delhi152577264303 Gujarat148297139915 Rajasthan76804341172 Madhya Pradesh70243689305 Uttar Pradesh67243824177 West Bengal40091486283 Andhra Pradesh3117206558 Bihar300680014 Karnataka240576245 Punjab2106191840 Telangana1991128457 Jammu and Kashmir175983324 Odisha15937337 Haryana130582416 Kerala9645426 Assam683634 Jharkhand4261534 Uttarakhand400644 Chhatisgarh360790 Chandigarh2781874 Tripura2321650 Himachal Pradesh223634 Goa67280 Puducherry49170 Manipur3940 Meghalaya20121 Nagaland900 Arunachal Pradesh210 Mizoram110 Sikkim100

Remdesivir shows 'clear-cut' effect in treating coronavirus, says US

AFP
Published : Apr 30, 2020, 9:36 am IST
Updated : Apr 30, 2020, 9:36 am IST

The finding represents the first time any medication has been shown to improve outcomes against the COVID-19 illness

 US says remdesivir shows 'clear-cut' effect in treating coronavirus. (Photo- Stig Alenäs | Dreamstime.com)
  US says remdesivir shows 'clear-cut' effect in treating coronavirus. (Photo- Stig Alenäs | Dreamstime.com)

WASHINGTON: COVID-19 patients who took the antiviral remdesivir recovered about 30 percent faster than those on a placebo, the results of a major clinical trial showed Wednesday, as the top US epidemiologist hailed the drug's "clear-cut" benefit.

The finding represents the first time any medication has been shown to improve outcomes against the COVID-19 illness, which has claimed more than 220,000 lives globally and ground the world economy to a halt.

The US National Institute of Allergy and Infectious Diseases (NIAID), which oversaw the trial, said that patients on the drug made by Gilead Sciences had a 31 percent faster time to recovery than those on a placebo.

"Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo," it said.

For Anthony Fauci, who leads the NIAID and has been one of the government's point people during the crisis, "the data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery."

"Although a 31 percent improvement doesn't seem like a knockout 100 percent, it is a very important proof of concept because what it has proven is that a drug can block this virus," he told reporters at the White House.

The results also suggested that people who were on the drug were less likely to die, although the difference was small. The mortality rate was 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group.

The trial began on February 21 and involved 1,063 people across 68 locations in the United States, Europe and Asia.

Neither the patients nor their physicians were aware of which group they belonged to, in order to eliminate unconscious bias.

Peter Horby, an epidemiologist at the University of Oxford who was not involved in the study, said: "We need to see the full results, but if confirmed this would be a fantastic result and great news for the fight against COVID-19."

President Donald Trump, who described the news as a "positive event," said he supported an emergency use authorization for the drug, which would allow doctors to prescribe it more widely.

The CEO of Gilead Sciences, the US laboratory that manufactures remdesivir, Daniel O'Day, said the company plans to donate the 1.5 million doses they have in stock enough to treat at least 140,000 patients.

The company would then sell the drug at an "affordable" price, he told the health news site Stat.

Tags: covid-19, coronavirus treatment, antiviral remdesivir, us national institute of allergy and infectious diseases, gilead sciences, us laboratory, placebo group
Location: United States, Washington, Seattle
ADVERTISEMENT
ADVERTISEMENT